The Roles of Vitamin D and Microbiome in Children With Post-acute COVID-19 Syndromes (PACS) and Long COVID
Post-acute COVID-19 Syndromes
About this trial
This is an interventional treatment trial for Post-acute COVID-19 Syndromes focused on measuring Post-acute COVID-19 Syndromes (PACS), Long COVID, human microbiome, vitamin D
Eligibility Criteria
Inclusion Criteria: Children aged 0-18 years The child sought/needed primary or secondary medical care for COVID-19 Laboratory (RT-PCR, COVID-19 antigen tests or SARS-CoV-2 antibody testing) or physician confirmed SARS-CoV-2 infection based on classic clinical symptoms and/or ground-glass opacification on CT imaging. 28 days - 3 months from the onset of COVID-19 symptoms Parent's/carer's/guardians consent to participate Exclusion Criteria: Recruit patients who have used antibiotics, systemic steroids, and immunosuppressants in the previous month. Patients with C1 esterase inhibitor deficiency, lymphocytopenia, thrombocytopenia, severe diseases involving heart, liver, or kidney, metabolic disease, or autoimmune disease.
Sites / Locations
- China Medical University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Experimental: Treatment group
Placebo Comparator: Control group
Vitamin D (2000IU/day) for 6 months
placebo